Elan's valuation is now just above €2bn. It has cash funds of €1.5bn

Irish drugs firm Elan, which has lost almost 73 percent of its value since Monday, following the suspension of trials of a key drug for multiple sclerosis, had fallen 3 cent, -0.47 percent, in Dublin on a volume of 1,273,682, just before the close of trading in Dublin Wednesday.

On Tuesday, the Elan share price fell 3 percent. Incorrect data provided by the Irish Stock Exchange, had indicated that the share had closed down 14 percent. For latest prices, check here.  

Elan began trading Monday with a valuation of €7.9bn ($10.5bn). In mid-2001, Elan was Ireland's top valued company with a valuation of $17bn. Today, its valuation is down to almost $2bn ($2.6bn). It still has a cash hoard of €1.5bn. 

Related:

Elan crashes 70% in value; Biogen Idec plunges 43%

Elan settles SEC fraud claims and pays $15 million fine

Irish drugs group Elan's ex-CEO Geaney to sue for unfair dismissal

Elan forecasts return to profitability by end 2006